Cerus Co. (NASDAQ:CERS – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.89 and traded as high as $2.07. Cerus shares last traded at $1.98, with a volume of 1,200,281 shares.
Wall Street Analysts Forecast Growth
Separately, Stifel Nicolaus lowered their price target on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, October 17th.
Cerus Stock Up 2.1 %
Cerus (NASDAQ:CERS – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. Cerus had a negative net margin of 11.19% and a negative return on equity of 37.90%. The business had revenue of $46.02 million during the quarter, compared to analyst estimates of $44.10 million. During the same period last year, the business posted ($0.03) earnings per share. As a group, research analysts expect that Cerus Co. will post -0.11 EPS for the current fiscal year.
Insider Activity at Cerus
In related news, Director Eric Bjerkholt sold 20,000 shares of Cerus stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $1.78, for a total transaction of $35,600.00. Following the transaction, the director now owns 162,133 shares in the company, valued at approximately $288,596.74. The trade was a 10.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.40% of the stock is owned by insiders.
Institutional Trading of Cerus
Large investors have recently added to or reduced their stakes in the company. R Squared Ltd purchased a new position in Cerus during the 4th quarter valued at $29,000. Creative Planning increased its position in Cerus by 51.3% during the 3rd quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 8,411 shares in the last quarter. PCA Investment Advisory Services Inc. acquired a new position in Cerus during the 4th quarter valued at about $46,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in Cerus by 38.4% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 35,074 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 9,737 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Cerus during the 3rd quarter valued at about $71,000. Institutional investors own 78.37% of the company’s stock.
About Cerus
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Recommended Stories
- Five stocks we like better than Cerus
- Roth IRA Calculator: Calculate Your Potential Returns
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Market Cap Calculator: How to Calculate Market Cap
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Canada Bond Market Holiday: How to Invest and Trade
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.